Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01JMC
|
|||
| Former ID |
DCL000872
|
|||
| Drug Name |
Lorcaserin
|
|||
| Synonyms |
APD 356; APD356; AR-10A; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 10-chloro-2-methyl-4-azabicyclo[5.4.0]undeca-8,10,12-triene
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Approved | [1], [2] | |
| Drug abuse [ICD-11: 6C4G.1Z; ICD-10: F19] | Phase 1 | [1], [3] | ||
| Company |
Arena Pharmaceuticals Inc.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H14ClN
|
|||
| Canonical SMILES |
CC1CNCCC2=C1C=C(C=C2)Cl
|
|||
| InChI |
1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1
|
|||
| InChIKey |
XTTZERNUQAFMOF-QMMMGPOBSA-N
|
|||
| CAS Number |
CAS 616202-92-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16769280, 23759570, 50076564, 56405331, 80942818, 81044375, 92719328, 93309628, 103443775, 104047951, 124894047, 126620900, 126651854, 126665802, 132608831, 135261408, 135650530, 135723896, 135727785, 137001355, 140812879, 144206569, 160644926, 160827934, 163093396, 163391282, 163620732, 163686045, 164228304, 164761636, 170466882, 170524167, 172087023, 175268181, 184816814, 198993060, 204431113, 223399569, 223565951, 223676318, 224280758, 226531083, 247440081, 249582104, 252438298
|
|||
| ChEBI ID |
CHEBI:65353
|
|||
| ADReCS Drug ID | BADD_D01319 ; BADD_D01320 ; BADD_D02448 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2C receptor (HTR2C) | Target Info | Agonist | [3], [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2941). | |||
| REF 2 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | |||
| REF 3 | Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. | |||
| REF 4 | Clinical pipeline report, company report or official report of Arena Pharmaceuticals (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.